Filing Flows › Insight Molecular Diagnostics (IMDX) › Q2 2026
Insight Molecular Diagnostics (IMDX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Insight Molecular Diagnostics (IMDX) reported revenue of $239K for the second quarter 2026 (Q2 2026), -54% from a year earlier and +647% from the quarter before.
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $239K | +647% | -54% |
| Operating profit | −$11.4M | — | — |
| Net earnings | −$11.3M | — | — |
| Operating cash flow | −$9.3M | — | — |
What changed
Revenue was $239K in Q2 2026, down 54% year over year and up 647% from the previous quarter. Laboratory Services was the largest line at 91% of revenue. Laboratory Services lost $276K year over year (down 56%), 99% of the total change.
Gross margin was 65.7%, up 0.4 points from Q2 2025. Operating costs exceeded revenue by $11.4M, an operating margin of -4770.7%. Operating expenses grew 14% against a revenue fall of 54%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $11.3M, wider than the previous quarter's $4.3M loss.
Operating cash flow was −$9.3M. Non-cash charges added back $665K of depreciation and amortization and $661K of share-based compensation. Working capital and other items added $666K. Capital expenditures of $779K exceeded it, leaving free cash flow of −$10.0M.
Questions
What was Insight Molecular Diagnostics' revenue in the second quarter 2026?
Insight Molecular Diagnostics (IMDX) reported revenue of $239K for the second quarter 2026 (Q2 2026), -54% from a year earlier and +647% from the quarter before.